GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics

Size: px
Start display at page:

Download "GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics"

Transcription

1 GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date): Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis): Changes from previous version (not applicable if this is a new guideline, enter below if extensive): Summary of evidence base this guideline has been created from: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Dr Abhijit Dixit Family Health Clinical Genetics Clinical Genetics department January 2019 Patients affected with or have a family history of breast and ovarian cancer. Please see guidelines for inclusion / exclusion criteria Previous version not on intranet Evidence 1 and 5 NICE -Familial breast cancer Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer Issued: June 2013 This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date or outside of the Trust. Page 1 of 15 1

2 GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Date: August 2015 Aim That individuals at an increased genetic risk of breast and / or ovarian cancer are offered evidence based care and information. Objectives 1. To target the use of resources consistently to ensure equity of service provision across our service. 2. To enable audit of the service. A small percentage of breast and ovarian cancer is due to the inheritance of a cancer susceptibility gene e.g. BRCA 1 and 2. Families who may be at increased risk to develop breast and / or ovarian cancer are identified on the basis of their family history of these two cancers. These guidelines include: A. Guidelines for referral of patients with a family history of breast / ovarian cancer from primary care to clinical genetics or a breast family history clinic. B. Guidelines for risk stratification of families with breast / ovarian cancer. C. Guidelines for the management of breast cancer risk. D. Guidelines for management of ovarian cancer risk. E. Guidelines for genetic testing of families with breast / ovarian cancer. Page 2 of 15 2

3 A. GUIDELINES FOR REFERRAL OF PATIENTS WITH A FAMILY HISTORY OF BREAST / OVARIAN CANCER FROM PRIMARY CARE: DIRECT REFERRAL TO CLINICAL GENETICS: Women with a non-mucinous ovarian cancer should be referred directly to Clinical Genetics REFERRAL TO BREAST FAMILY HISTORY CLINIC: Patients with the following family histories of cancer, all on the same side of the family, are at increased risk and should be referred: 3 relatives Three or more 1 st or 2 nd degree relatives with breast and / or ovarian cancer. 2 relatives One 1 st and one 1 st or 2 nd degree relative with breast cancer. One 1 st or 2 nd degree relative with breast cancer and one 1 st or 2 nd degree relative with ovarian cancer *. Two 1 st or 2 nd degree relatives with ovarian cancer*. One 1 st or 2 nd degree relative with breast cancer and one 1 st or 2 nd degree relative with either a sarcoma < 45, a glioma or a childhood adrenal cortical carcinoma*. 1 relative A 1 st degree relative with breast cancer under 40. A 1 st degree relative with bilateral breast cancer. A 1 st degree relative with male breast cancer. A 1 st degree relative with both breast and ovarian cancer. First degree relatives include parents, siblings and children. Second degree relatives include grandparents, aunts and uncles, nephews and nieces. * One should be a first degree relative unless the family history is on the paternal side of the family. Page 3 of 15 3

4 B. GUIDELINES FOR THE RISK STRATIFICATION OF FAMILIES WITH BREAST / OVARIAN CANCER The family history can be defined as being low, moderate or high risk. Low risk - less than 2 x lifetime risk of breast cancer Moderate risk x lifetime risk of breast cancer High risk - greater than 3 x lifetime risk of breast cancer Patients with the following family histories, on the same side of the family, fall into the moderate and high risk groups: MODERATE RISK 3 Relatives Three 1 st or 2 nd degree relatives with breast cancer at an average age of over 60*. One relative with ovarian cancer and two 1 st or 2 nd degree relatives with breast cancer where the average age for the breast cancer is over 60*. 2 relatives One 1 st degree relative and one 1 st or 2 nd degree relative with an average age of breast cancer over 50 and under 60*. One ovarian cancer and one 1 st or 2 nd degree relative with breast cancer over 50*. One 1 st or 2 nd degree relative with bilateral breast cancer and one 1 st or 2 nd degree relative with breast cancer over 60* 1 Relative A 1 st degree relative with breast cancer under 40. A 1 st degree relative with male breast cancer at any age. A 1 st degree relative with bilateral breast cancer, where the average age of diagnosis is over 50. First degree relatives include parents, siblings and children. Second degree relatives include grandparents, aunts and uncles, nephews and nieces. * One should be a first degree relative unless the family history is on the paternal side of the family. Page 4 of 15 4

5 HIGH RISK 4 or more relatives Four or more close relatives with breast and / or ovarian cancer*. 3 Relatives Three 1 st or 2 nd degree relatives with an average age of breast cancer under 60*. One relative with ovarian cancer and two 1 st or 2 nd degree relatives with breast cancer where the average age for the breast cancer is under 60*. One male breast cancer at any age and 2 female breast cancers with an average age under 60 2 Relatives One 1 st and one 1 st or 2 nd degree relative with an average age of breast cancer under 50. One 1 st and one 1 st or 2 nd degree relative with ovarian cancer. One ovarian cancer and one 1 st or 2 nd degree relative with breast cancer under 50*. One 1 st or 2 nd degree relative with bilateral breast cancer and one 1 st or 2 nd degree relative with breast cancer under 60* or ovarian cancer at any age One male breast cancer at any age and a female breast cancer under 50 or an ovarian cancer at any age 1 Relative A 1 st degree relative with both breast cancer under 50 and ovarian cancer. A 1 st degree relative with bilateral breast cancer, both under 50. First degree relatives include parents, siblings and children. Second degree relatives include grandparents, aunts and uncles, nephews and nieces. * One should be a first degree relative unless the family history is on the paternal side of the family. Page 5 of 15 5

6 C. GUIDELINES FOR THE MANAGEMENT OF BREAST CANCER RISK The management of individuals with a family history of breast / ovarian cancer is determined by their risk calculated on the basis of their family history and genetic testing. Low risk Individuals at low risk do not require any other than that offered to the general under the National Breast Screening programme. Moderate risk Individuals at moderate risk may benefit from earlier and more frequent breast by. Current recommendations are that: 1) Women at moderate risk should be offered additional breast by. 2) should commence at 40 and performed yearly until the age of 50, then to consider annual and then women are transferred to the National Breast Screening programme. High risk Individuals at high risk may also benefit from earlier and more frequent breast by and/or scan. They should also be offered referral to the Clinical Genetics department for genetic counselling including the possibility of genetic testing in the family. Table 1 summarises the surveillance recommendations for women with a AT mutation Table 2 summarises the surveillance recommendations for subgroups within the high-risk category for specific guidelines. Some women in the categories; a) <30% chance of a BRCA or TP53 mutation, and b) untested but >30% chance of a BRCA or TP53 mutation, will be eligible for indirect BRCA genetic testing. It is, therefore, important to calculate their personal risk of a BRCA mutation using Manchester score or BOADICEA. Table 1 Recommendations for women with AT mutations: Risk Ages Surveillance Protocol Frequenc y Notes A-T homozygotes 25+ No A-T heterozygotes monthly Routine (3 yearly) Routine from 50 Page 6 of 15 6

7 Age Table 2 Moderate risk of breast cancer 1 High risk of breast cancer (but with a 30% or lower BRCA ortp5 3 carrier probability) 2 Untested but greater than 30% BRCA carrier probability 3 Known BRCA1 or BRCA2 mutation Untested but greater than 30% TP53 carrier probability 4 Known TP53 mutation f recommendations on surveillance for women with no personal history of breast cancer S u m m a r y o Consider annual and consider annual and consider annual mammograph y and annual and annual Consider annual mammograph y unless dense breast pattern unless dense breast pattern programme unless dense breast pattern Consider annual programme programme programme unless dense breast pattern unless dense breast pattern programme unless dense breast pattern Consider annual 70+ Page 7 of 15 7

8 programme programme programme programme programme 1 Lifetime risk of developing breast cancer is at least 17% but less than 30%. 2 Lifetime risk of developing breast cancer is at least 30%. High risk group includes rare conditions that carry an increased risk of breast cancer, such as Peutz-Jeghers syndrome, (STK11), Cowden (PTEN), familial diffuse gastric cancer (E-Cadherin). 3 Surveillance recommendations for this group reflect the fact that women who at first assessment had a 30% or greater BRCA carrier probability and reach 60 years of age without developing breast or ovarian cancer will now have a lower than 30% carrier probability and should no longer be offered surveillance. 4 Surveillance recommendations for this group reflect the fact that women who at first assessment had a 30% or greater TP53 carrier probability and reach 50 years of age without developing breast cancer or any other TP53- related malignancy will now have a lower than 30% carrier probability and should no longer be offered surveillance. Page 8 of 15 8

9 D. GUIDELINES FOR THE MANAGEMENT OF OVARIAN CANCER RISK BRCA testing: BRCA1/2 testing should be offered to individuals who fulfil genetic testing criteria as outlined in section E. Management of ovarian risk: Ovarian risk should be discussed: In women with BRCA1 or BRCA2 mutations. In BRCA1/2 negative families, only discuss ovarian risk if the consultee has two or more first or second-degree relatives with ovarian cancer. At least one should be a first-degree relative of the consultee. At least two of the ovarian cancer cases should be first-degree relatives of each other. In BRCA1/2 negative families with breast cancer only, no discussion, surveillance or riskreducing surgery for ovarian cancer is required. There is no evidence of a significant increase in ovarian cancer risk in such families. Risk-reducing bilateral salpingo-oophorectomy Risk-reducing bilateral salpingo-oophorectomy can be considered after child-bearing is complete. Ovarian Ovarian is known to have both a high false positive rate and a high false negative rate and should not be recommended outside of a research study. Ovarian options currently differ in different regions and management of increased ovarian cancer risk remains the responsibility of the gynaecologist offering this service. All women who have taken part in UKFOCSS should be offered review at the end of the study by the gynaecologist coordinating their to discuss options. Page 9 of 15 9

10 E. GUIDELINES FOR GENETIC TESTING OF FAMILIES WITH BREAST / OVARIAN CANCER. Individuals with breast or ovarian cancer who fall into the high risk group can be offered genetic testing in order to try to identify a mutation in one of the BRCA genes. Individuals who undergo genetic testing must: 1) be referred to the Clinical Genetics department 2) receive genetic counselling about the implications of a positive result which would include discussion about, psychosocial well-being and the wider implications. 3) give informed, written consent for the test. 4) If the patient is terminally ill blood can be taken by the referring physician for DNA storage. Genetic counselling and discussion of testing can be performed at a later stage but the patient must identify a family member to whom the result can be given. Criteria for a diagnostic genetic test Please see table 3 for a full list of who should be offered a diagnostic genetic test. Criteria for a predictive genetic test Members of families where a mutation has been identified should be referred to a clinical geneticist to discuss predictive testing. 1) Individuals should be over 16 2) They should receive genetic counselling prior to the blood being taken which should include options, discussion of prophylactic surgery, psychosocial issues and the wider implications of the result. Other conditions to consider in families with breast cancer Consider the possibility of other conditions that increase the risk of breast cancer, particularly if BRCA testing is negative. 1) Think about Li-Fraumeni syndrome (TP53) in families with young-onset breast cancers, particularly if associated with sarcomas, adrenocortical tumours, or any other unusually young-onset cancers. Women with breast cancer <30 years should be offered TP53 testing. 2) Consider Cowden syndrome (PTEN) in families with breast cancer, thyroid cancer (particularly follicular) and endometrial carcinoma. Macrocephaly and mucocutaneous lesions can be important pointers on examination, so consider assessing for these at appointments. Overgrowth, seizures and learning difficulties can be seen in children with Cowden syndrome. Other thyroid lesions (adenomas, multinodular goitre) and breast fibrocystic disease are also part of the Cowden syndrome spectrum, as are lipomas and fibromas. Individuals eligible for the BOCS research study but not for clinical BRCA 1. A woman affected with breast cancer who has 2 relatives with ovarian or breast cancer (e.g. could be 3 women with late breast cancer) 2. A woman affected with bilateral breast cancer regardless of age at diagnosis. 3. Please note that women cannot be referred to clinical genetics purely for enrolment into the BOCS research study. Any unsuitable referrals will be returned to the referrer. Page 10 of 15 10

11 A 4. A man affected with breast cancer (i.e. Manchester score <14). 5. Table 3: Guidelines for BRCA1 and BRCA2 diagnostic genetic testing Woman with breast cancer who 1. has a breast cancer diagnosed under the age of has bilateral breast cancer and both cancers diagnosed <50 yr 3. has triple negative breast cancer diagnosed <50 yr 4. has non-mucinous epithelial ovarian cancer 5. has bilateral breast cancer and a relative with breast cancer <60 yr 6. has a relative with breast cancer and both diagnosed <45 yr 7. has relatives with breast/ovarian cancer and Manchester score 15 B Woman with ovarian cancer who 1. has non-mucinous epithelial ovarian cancer (e.g serous or endometrioid) C Man with breast cancer who 1. has a relative with a non-mucinous ovarian cancer or male breast cancer 2. has relatives with breast cancer and Manchester score 15 D Individual unaffected with cancer who 1. has at least one first degree relative with breast/ovarian cancer and familial Manchester score has first degree relative with ovarian cancer and familial Manchester score 17 Key Relative = first degree or second degree relative only, except when calculating Manchester score* Triple negative breast cancer = breast tumour negative for oestrogen receptor (ER)*, progesterone receptor (PR) and HER2 expression $ Ovarian cancer scoring: A serous peritoneal primary tumour or fallopian tube cancers should be considered as if an ovarian cancer Manchester Score Cancer, age at diagnosis Score Breast Cancer, <30 11 Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, >59 2 Breast Cancer, <60 13 Breast Cancer, >59 10 Ovarian Cancer,<60 13 Ovarian Cancer, >59 10 Pancreatic Cancer 1 Prostate Cancer, <60 2 Prostate Cancer, >59 1 Page 11 of 15 11

12 See accompanying FAQs for common queries. Pathology adjustments to Manchester Score are no longer required. Women with triple negative breast cancer diagnosed <50 years are eligible for BRCA testing (see A2 above). Ovarian cancer histology Diagram 1: Origins of the three main types of ovarian cancer i Any patient with a non mucinous, non germ cell, non sex cord, non-borderline ovarian tumors should be offered BRCA1/2 testing and counted as an ovarian cancer when assessing whether to offer BRCA1/2 testing. A serous peritoneal primary tumour or fallopian tube cancers should be considered as if an ovarian cancer. Serous and endometrioid ovarian tumours are strongly associated with BRCA mutations. Mucinous and borderline cancers are not associated with BRCA mutations and should not be considered when assessing risk of BRCA mutation in families. Consider possibility of Lynch syndrome if history of bowel or endometrial cancer in family. Other ovarian cancer types such as sex-cord or germ cell have not been strongly associated with a BRCA1/2 mutations. Other types of epithelial-stroma ovarian cancers except mucinous or borderline cancer should be counted as an ovarian cancer when assessing whether to offer BRCA1/2 testing Page 12 of 15 12

13 From: Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. DGR Evans et al. J Med Genet 2005; 42: e39 Page 13 of 15 13

14 Ashkenazi Jewish ancestry: Approximately 2% of general Ashkenazi (4 Ashkenazi grandparents), and 10% of Ashkenazi women with breast cancer carry BRCA1 or BRCA2 founder mutations. Breast cancer penetrance is lower with the common mutations: BRCA1-56% by 70, BRCA2-25% by 70 Author: Dr A Dixit August 2015 Review Date: Dr A Dixit January 2019 References NICE Guideline Familial Breast Cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. Issued October 2007 NICE Guideline CG164- Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Issued June 2013 Page 14 of 15 14

15 Eccles DM et al. Guidelines for a genetic risk based approach to advising women with a family history of cancer. J Med Genet 2000; 37:203-9 Report of Consensus meeting on the management of women with a family history of breast cancer. Public Health Genetics 1998 Evans DGR et al. A new scoring system for the chances of identifying a BRCA 1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004; 41: Evans DGR et al. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 2005; 42: e39 Evans DGR et al. Additional pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 system. J Med Genet 2009; 46: Kwon JS et al. Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors J Clin Oncol 2010; 28: Lakhani SR et al. The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers, Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients with Mutations in BRCA1 and BRCA2. J. Clin. Oncol : Version 3 i Page 15 of 15 15

Identification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.

Identification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation. Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification

More information

Eligibility criteria for prophylactic treatment allowance

Eligibility criteria for prophylactic treatment allowance Eligibility criteria for prophylactic treatment allowance Southern Cross will only pay the prophylactic treatment allowance for the following healthcare services when the applicable eligibility criteria

More information

Risk Assessment and Risk Management

Risk Assessment and Risk Management Risk Assessment and Risk Management Epworth Benign Breast Disease Symposium Dr Laura Chin-Lenn 12 November 2016 Why identify those at increased risk of breast cancer? Should I be worried? 1 Why identify

More information

Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164

Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164

More information

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are

More information

Advice about familial aspects of breast cancer and epithelial ovarian cancer

Advice about familial aspects of breast cancer and epithelial ovarian cancer Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals

More information

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents

More information

Reference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016

Reference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016 Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have

More information

Cancer Genomics 101. BCCCP 2015 Annual Meeting

Cancer Genomics 101. BCCCP 2015 Annual Meeting Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic

More information

Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer

Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017

More information

Genetic Testing for BRCA1 and BRCA2 Genes

Genetic Testing for BRCA1 and BRCA2 Genes Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling

More information

Hereditary Breast and Ovarian Cancer Screening & Genetic Counseling

Hereditary Breast and Ovarian Cancer Screening & Genetic Counseling Hereditary Breast and Ovarian Cancer Screening & Genetic Counseling Cecelia Bellcross, PhD, MS, CGC Emory University School of Medicine Department of Human Genetics The First Line of Defense February 21,

More information

BRCA Precertification Information Request Form

BRCA Precertification Information Request Form BRCA Precertification Information Request Form Failure to complete this form in its entirety may result in the delay of review. Fax to: BRCA Precertification Department Fax number: 1-860-975-9126 Section

More information

So how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.

So how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent. Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high

More information

Primary Care Approach to Genetic Cancer Syndromes

Primary Care Approach to Genetic Cancer Syndromes Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)

More information

GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department

GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY

More information

Policy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP

Policy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP Retired Date: Page 1 of 9 1. POLICY DESCRIPTION: BRCA 1&2 Genetic Testing 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claim

More information

WHAT DO GENES HAVE TO DO WITH IT? Breast Cancer Risk Assessment and Risk Reduction in 2016

WHAT DO GENES HAVE TO DO WITH IT? Breast Cancer Risk Assessment and Risk Reduction in 2016 WHAT DO GENES HAVE TO DO WITH IT? Breast Cancer Risk Assessment and Risk Reduction in 2016 39 th Annual CANP Educational Conference March 17 20, 2016 Collaborate. Educate. Advocate. Karen Herold, DNP,

More information

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017 Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA

More information

Genetic Testing for BRCA1 and BRCA2 Genes

Genetic Testing for BRCA1 and BRCA2 Genes Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is

More information

Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian

Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian ANNOUNCER OPEN: Welcome to CME on ReachMD. This segment, entitled Inherited Susceptibility to Cancer: What Do Primary Care Providers

More information

GeneHealth BreastGene_New qxp_Layout 1 21/02/ :42 Page 3 BreastGene GeneHealth UK

GeneHealth BreastGene_New qxp_Layout 1 21/02/ :42 Page 3 BreastGene GeneHealth UK GeneHealth BreastGene_New 8.2.17.qxp_Layout 1 21/02/2017 16:42 Page 3 BreastGene GeneHealth UK BreastGene What is hereditary breast cancer? Breast cancer is the most common cancer in the UK. Unfortunately

More information

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast

More information

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013 Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:

More information

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch

More information

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013 For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Moderate Penetrance Variants Associated with Breast Cancer in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: moderate_penetrance_variants_associated_with_breast_cancer_

More information

Ovarian Cancer Causes, Risk Factors, and Prevention

Ovarian Cancer Causes, Risk Factors, and Prevention Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.

More information

Myriad Financial Assistance Program (MFAP)

Myriad Financial Assistance Program (MFAP) Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.

More information

This information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.

This information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164. Familial breast cancer (breast cancer in the family) Information for the public Published: 1 June 2013 nice.org.uk About this information NICE guidelines provide advice on the care and support that should

More information

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which

More information

Update on BRCA testing thresholds NICE guidance changes

Update on BRCA testing thresholds NICE guidance changes Update on BRCA testing thresholds NICE guidance changes D Gareth R Evans Christie and St Mary s Hospital Manchester UK London July 2014 Guideline Development Group Familial Breast Cancer Any woman with

More information

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer

More information

CANCER GENETICS PROVIDER SURVEY

CANCER GENETICS PROVIDER SURVEY Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded

More information

Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center

Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling

More information

Precision Medicine and Genetic Counseling : Is Yes always the correct answer?

Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)

More information

Genetic Screening Visit

Genetic Screening Visit Before your visit In a typical hereditary breast ovarian cancer genetic counsling visit be prepared to answer the following set of questions, please check were applicable. About your self (same questions

More information

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,

More information

Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center

Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Disclosure- I DO NOT HAVE any relevant financial interest with any entity producing,

More information

MANAGEMENT OF HIGH RISK BREAST PATIENTS DR PAMELA THOMPSON BREAST PHYSICIAN, FSH

MANAGEMENT OF HIGH RISK BREAST PATIENTS DR PAMELA THOMPSON BREAST PHYSICIAN, FSH MANAGEMENT OF HIGH RISK BREAST PATIENTS DR PAMELA THOMPSON BREAST PHYSICIAN, FSH HIGH RISK MANAGEMENT OBJECTIVES Be alert to FHx Breast and/or Ovarian cancer Know how to perform a risk assessment Be aware

More information

Coversheet for Network Site Specific Group Agreed Documentation

Coversheet for Network Site Specific Group Agreed Documentation Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance

More information

Genetic Determinants, Risk Assessment and Management

Genetic Determinants, Risk Assessment and Management Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon

More information

BRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY

BRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime

More information

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2 GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2 Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Hereditary Cancer Update: What do GPOs need to know?

Hereditary Cancer Update: What do GPOs need to know? Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to

More information

Hereditary Cancer Products

Hereditary Cancer Products Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed

More information

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. MRI OF THE BREAST Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Management of women at high risk of breast cancer

Management of women at high risk of breast cancer Follow the link from the online version of this article to obtain certified continuing medical education credits Management of women at high risk of breast cancer Anne C Armstrong, 1 Gareth D Evans 2 3

More information

Predictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD

Predictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex

More information

Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?

Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:

More information

Genetic Testing: who, what, why?

Genetic Testing: who, what, why? Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk

More information

MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14, 09/15/15.

MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14, 09/15/15. MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,

More information

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes. Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer

More information

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2 SYNDROME BRCA1 BRCA2 Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association BRCA1 and BRCA2 Testing Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member

More information

Hereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com

Hereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic

More information

Applies to: All Aetna plans, except Traditional Choice plans. All Innovation Health plans, except indemnity plans

Applies to: All Aetna plans, except Traditional Choice plans. All Innovation Health plans, except indemnity plans BRCA Precertification Information Request Form Applies to: All Aetna plans, except Traditional Choice plans All Innovation Health plans, except indemnity plans All Health benefits and health insurance

More information

Management of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH

Management of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number

More information

MP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers

MP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019

More information

Medical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011

Medical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011 Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective

More information

Hereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with

Hereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with Hereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with positive and negative results? SAMO Workshop Luzern 3./4.10.2014 Dr. med. Barbara Bolliger TumorTumor-

More information

I have ovarian cancer

I have ovarian cancer I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (NHS England only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent

More information

HEREDITARY CANCER SYNDROMES: IDENTIFYING THOSE AT RISK

HEREDITARY CANCER SYNDROMES: IDENTIFYING THOSE AT RISK HEREDITARY CANCER SYNDROMES: IDENTIFYING THOSE AT RISK OCTOBER 20, 2017 JESSICA CARY, MS, RN, CGC cary@newecs.org GENETIC COUNSELOR OBJECTIVES 1) Taking a Cancer Family History 2) Identify patients and/or

More information

Information leaflet for women with an increased lifetime risk of breast and ovarian cancer. Hereditary Breast and Ovarian Cancer (HBOC)

Information leaflet for women with an increased lifetime risk of breast and ovarian cancer. Hereditary Breast and Ovarian Cancer (HBOC) Information leaflet for women with an increased lifetime risk of breast and ovarian cancer Hereditary Breast and Ovarian Cancer (HBOC) What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast

More information

Genetic testing for gynaecological cancer

Genetic testing for gynaecological cancer Genetic testing for gynaecological cancer Gaba, FM; Manchanda, R 2016 Elsevier Ltd. For additional information about this publication click this link. http://qmro.qmul.ac.uk/xmlui/handle/123456789/18971

More information

Clinical options for mutations of BRCA 1/2 genes. Ioannis Th. Natsiopoulos Breast surgeon

Clinical options for mutations of BRCA 1/2 genes. Ioannis Th. Natsiopoulos Breast surgeon Clinical options for mutations of BRCA 1/2 genes Ioannis Th. Natsiopoulos Breast surgeon The detection of a BRCA mutation is not diagnosis of a disease; it is genetic information and risk assessment Indications

More information

BRCA1 & BRCA2 GeneHealth UK

BRCA1 & BRCA2 GeneHealth UK BRCA1 & BRCA2 GeneHealth UK BRCA1 & BRCA2 What is hereditary breast cancer? Cancer is unfortunately very common, with 1 in 2 people developing cancer at some point in their lifetime. Breast cancer occurs

More information

I have ovarian cancer

I have ovarian cancer I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (Scotland only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent

More information

Page 1 of 8 TABLE OF CONTENTS

Page 1 of 8 TABLE OF CONTENTS Page 1 of 8 TABLE OF CONTENTS Patient Evaluation and Recommendation..Page 2 Testing and Follow-up..Page 3 Genetic Counseling Referral Criteria.....Page 4-5 Patient Education..Page 6 Suggested Readings...Page

More information

patient education Fact Sheet

patient education Fact Sheet patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are

More information

GeneHealth BRCA 1&2_ qxp_Layout 1 21/02/ :44 Page 3 BRCA1 & BRCA2 GeneHealth UK

GeneHealth BRCA 1&2_ qxp_Layout 1 21/02/ :44 Page 3 BRCA1 & BRCA2 GeneHealth UK GeneHealth BRCA 1&2_8.2.17.qxp_Layout 1 21/02/2017 16:44 Page 3 BRCA1 & BRCA2 GeneHealth UK GeneHealth BRCA 1&2_8.2.17.qxp_Layout 1 21/02/2017 16:44 Page 4 BRCA1 & BRCA2 What is hereditary breast cancer?

More information

Policy #: 259 Latest Review Date: November 2009

Policy #: 259 Latest Review Date: November 2009 Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.

More information

Genetic Risk Assessment for Cancer

Genetic Risk Assessment for Cancer Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient

More information

Multigene Panel Testing for Hereditary Cancer Risk

Multigene Panel Testing for Hereditary Cancer Risk Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline

More information

BRCAplus. genetic testing for hereditary breast cancer

BRCAplus. genetic testing for hereditary breast cancer BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial

More information

Genetic/Familial High-Risk Assessment: Breast and Ovarian

Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical in Oncology Genetic/Familial High-Risk Assessment: Breast and Ovarian V.1.2009 Continue www.nccn.org Assessment: Panel Members * Mary B. Daly, MD, PhD/Chair Fox Chase Cancer Center Jennifer E.

More information

Does Cancer Run in Your Family?

Does Cancer Run in Your Family? Does Cancer Run in Your Family? A Patient s Guide to Hereditary Breast and Ovarian Cancer Syndrome What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that

More information

Genetic Risk Assessment for Cancer

Genetic Risk Assessment for Cancer Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role

More information

Annual MRI Breast Screening Criteria Based Access Policy Date Adopted: 21st August 2015 Version:

Annual MRI Breast Screening Criteria Based Access Policy Date Adopted: 21st August 2015 Version: Annual MRI Breast Screening Criteria Based Access Policy Date Adopted: 21st August 2015 Version: 1516.2 Document Control Title of document Annual MRI Breast Screening Authors job title(s) IFR Manager Document

More information

Dr Marion Harris (Medical Oncologist)

Dr Marion Harris (Medical Oncologist) Dr Marion Harris (Medical Oncologist) 1. Cancer genetic testing and surveillance for familial breast and colorectal cancer What does an FCC do? Collect, assess and VERIFY a FHx of cancer Questionnaire

More information

GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics

GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer

More information

HEREDITY & CANCER: Breast cancer as a model

HEREDITY & CANCER: Breast cancer as a model HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic

More information

HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.

HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify

More information

Genetic/Familial High-Risk Assessment: Breast and Ovarian

Genetic/Familial High-Risk Assessment: Breast and Ovarian NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 2.2016 NCCN.org Continue Version 2.2016, 03/15/16 National Comprehensive

More information

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome

More information

Clinical Genetics Service

Clinical Genetics Service October 2012 Issue 1 Clinical Genetics Service Who provides your local Genetics Service? The Clinical Genetics department at Great Ormond Street Hospital (GOSH) covers a population of 4.5 million in North

More information

Sporadic Cancer - Cancer which occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer.

Sporadic Cancer - Cancer which occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer. to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer testing is right for you and should be reviewed with a trained healthcare

More information

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES

More information

Genetic/Familial High-Risk Assessment: Breast and Ovarian

Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2005 Continue Assessment: Panel Members * Mary B. Daly, MD, PhD/Chair Fox Chase Cancer Center Jennifer E. Axilbund, MS, CGS

More information

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome

More information

Cigna Medical Coverage Policy

Cigna Medical Coverage Policy Cigna Medical Coverage Policy Subject Prophylactic Mastectomy Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 7 References... 8 Effective Date... 8/15/2014

More information

Page 1 of 5 Home > Research & Grants > Research and Scientific Programs > What is genetic testing for breast cancer and who should get it? What is genetic testing for breast cancer and who should get it?

More information

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC Importance of Family History in Gynecologic Cancer Prevention Angela Thompson, MS, CGC Genetic Counselor Froedtert & The Medical College of Wisconsin Objectives Introduce role of genetic counselor Discuss

More information

HBOC. Jessica M. Salamone, ScM, CGC

HBOC. Jessica M. Salamone, ScM, CGC HBOC Jessica M. Salamone, ScM, CGC Certified Genetic Counselor Director of the Cancer Risk Assessment & Genetic Counseling Program Elizabeth Wende Breast Care, LLC Elizabeth Wende Breast Care Internationally

More information

Information for You and Your Family

Information for You and Your Family Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the

More information

Genetic Panel Testing and Implications for Cancer Care

Genetic Panel Testing and Implications for Cancer Care Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016

More information

Inherited Ovarian Cancer Diagnosis and Prevention

Inherited Ovarian Cancer Diagnosis and Prevention Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics

More information

GHUK BowelGene_2017.qxp_Layout 1 22/02/ :22 Page 3 BowelGene

GHUK BowelGene_2017.qxp_Layout 1 22/02/ :22 Page 3 BowelGene GHUK BowelGene_2017.qxp_Layout 1 22/02/2017 10:22 Page 3 BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK.

More information

Prophylactic Mastectomy

Prophylactic Mastectomy Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 08/24/2012 Section: Surgery Place(s) of Service: Inpatient I.

More information